Remibrutinib in Chronic Spontaneous Urticaria
Treatment with oral remibrutinib resulted in a significant improvement in a composite measure of itching and hives at week 12. (Funded by Novartis Pharmaceuticals; REMIX-1 and REMIX-2 ClinicalTrials.gov numbers, NCT05030311 and NCT05032157, respectively.).
Authors
- Noriko Seko
- Michihiro Hide (ORCID: https://orcid.org/0000-0002-1569-6034)
- Sarbjit Saini
- Mark Lebwohl (ORCID: https://orcid.org/0000-0002-4705-5303)
- Gordon Sussman (ORCID: https://orcid.org/0000-0002-2202-2513)
- R. Szalewski
- Giselle Mosnaim (ORCID: https://orcid.org/0000-0002-9874-3472)
- Artem Zharkov
- Martin Metz (ORCID: https://orcid.org/0000-0002-4070-9976)
- A.M. Giménez-Arnau
- E.D. Martzloff
- Sibylle Haemmerle
- Marcus Maurer (ORCID: https://orcid.org/0000-0002-4121-481X)
- Pengpeng Wang (ORCID: https://orcid.org/0000-0003-2160-9360)
- K. Lheritier
Institutions
- Hiroshima University (JP)
- Novartis (Switzerland) (CH)
- NorthShore University HealthSystem (US)
- Universitat Pompeu Fabra (ES)
- University of Toronto (CA)
- Humboldt-Universität zu Berlin (DE)
- Novartis (China) (CN)
- Hiroshima City Asa Citizens Hospital (JP)
- Novartis (Japan) (JP)
- Fraunhofer Institute for Translational Medicine and Pharmacology (DE)
- Allergy Associates Research Center (US)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- New England Journal of Medicine
- Published
- 2025-03-05
- DOI
- https://doi.org/10.1056/nejmoa2408792
- Citations
- 65
- Primary Topic
- Urticaria and Related Conditions
- Type
- article
- Field-Weighted Citation Impact
- 108.42